Codexis Launches Codex® HiTemp Reverse Transcriptase to Address Key Challenges in One-Step Assays for RNA Detection in PCR Testing, including COVID-19 Testing

Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced the launch of its Codex® HiTemp Reverse Transcriptase for use in one-step quantitative reverse transcription PCR (RT-qPCR).

Related Keywords

John Nicols ,Codexis Inc ,Nasdaq ,From Codexisdec ,Hitemp Reverse Transcriptase ,Reverse Transcriptase ,Na ,Iagnostic ,Nzyme ,Life Science ,Ucleic Acid ,Cars ,Ars Cov 2 ,Ranscription ,